Jupiter Topco LLC Acquires Shares of 8,579,881 IDEAYA Biosciences, Inc. $IDYA

Jupiter Topco LLC bought a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 8,579,881 shares of the company’s stock, valued at approximately $319,728,000. Jupiter Topco LLC owned approximately 0.10% of IDEAYA Biosciences as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Farther Finance Advisors LLC lifted its holdings in IDEAYA Biosciences by 171.1% during the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after purchasing an additional 580 shares during the last quarter. Quantbot Technologies LP bought a new stake in IDEAYA Biosciences during the second quarter worth about $43,000. ANTIPODES PARTNERS Ltd increased its holdings in shares of IDEAYA Biosciences by 49.4% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock worth $40,000 after buying an additional 380 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in shares of IDEAYA Biosciences during the fourth quarter worth approximately $61,000. Finally, Comerica Bank raised its stake in shares of IDEAYA Biosciences by 36.5% in the fourth quarter. Comerica Bank now owns 2,514 shares of the company’s stock valued at $87,000 after acquiring an additional 672 shares during the last quarter. Institutional investors own 98.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on IDYA shares. Wedbush increased their price target on IDEAYA Biosciences from $58.00 to $60.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Friday, July 17th. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a report on Friday, May 22nd. Truist Financial decreased their target price on IDEAYA Biosciences from $63.00 to $59.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. Finally, Mizuho lowered their target price on IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Fourteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $50.12.

Insider Buying and Selling

In other news, CAO Briseno Andres Ruiz sold 9,550 shares of IDEAYA Biosciences stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total value of $382,095.50. Following the completion of the sale, the chief accounting officer directly owned 26,466 shares of the company’s stock, valued at approximately $1,058,904.66. This trade represents a 26.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.70% of the company’s stock.

IDEAYA Biosciences Price Performance

IDYA opened at $42.48 on Wednesday. IDEAYA Biosciences, Inc. has a one year low of $23.23 and a one year high of $42.68. The company’s 50 day simple moving average is $36.57 and its 200-day simple moving average is $32.98. The stock has a market capitalization of $3.73 billion, a P/E ratio of -21.90 and a beta of -0.10.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.16). IDEAYA Biosciences had a negative net margin of 75.93% and a negative return on equity of 16.73%. The company had revenue of $8.86 million during the quarter, compared to analyst estimates of $8.02 million. During the same period in the prior year, the business earned ($0.88) EPS. The business’s revenue for the quarter was up 8800.0% on a year-over-year basis. As a group, analysts anticipate that IDEAYA Biosciences, Inc. will post -4.38 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.